Mrna-encoded antibody against the novel sars-COV-2. This agreement is to perform optimization work culminating in a phase i clinical trial of an mrna construct that encodes a lead sars-COV-2…
Other Transaction IDV Awarded Last action
- Contract number
- HR00112090078
- Awardee
-
Modernatx, Inc. UEI WJYNZ8AK2D47
- Awarding agency
-
Defense Advanced Research Projects Agency
Department of Defense
- Task orders
- 0
Award facts
- Last date to order
- Not on record
- IDV ceiling
- $7,852,706.00
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
Award details come from SAM.gov/FPDS.
About this IDV
This Other Transaction IDV was awarded on June 13, 2020 by the Defense Advanced Research Projects Agency to Modernatx, Inc. The potential value is $7,852,706. The agreement is to perform optimization work culminating in a Phase I clinical trial of an mRNA construct that encodes a lead SARS-CoV-2 antibody candidate in support of COVID-19 response efforts.
Specifically, the prime contractor will develop an optimized mRNA-encoded antibody against the novel SARS-CoV-2 virus. Work will include mRNA construct design, non-clinical testing, manufacturing process development and scale-up, and a first-in-human Phase I clinical trial. There was no set-aside designation specified. The potential value reflects the government's maximum liability should all optional tasks be exercised. Place of performance will likely include the prime contractor's facilities.
The award aims to procure mRNA-based antibody therapeutic development services to support COVID-19 medical countermeasure efforts. The Defense Advanced Research Projects Agency has invested in mRNA technologies for several years and is well positioned to expedite antibody therapeutic candidates into clinical testing through this mechanism.
Description
Mrna-encoded antibody against the novel sars-COV-2. This agreement is to perform optimization work culminating in a phase i clinical trial of an mrna construct that encodes a lead sars-COV-2 antibody candidate. Covid-19
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$329,196 | |
| Funding Only Action | -$1,459,756 | |
| Funding Only Action | -$8,659,180 | |
| Funding Only Action | -$7,428,013 | |
| Original award | $25,728,851 |
Quick answers
Who was awarded contract HR00112090078?
HR00112090078 was awarded to Modernatx, Inc. by Defense Advanced Research Projects Agency (Department of Defense) on June 13, 2020.
How much is contract HR00112090078 worth?
HR00112090078's own ceiling is $7,852,706.
Was contract HR00112090078 competed?
The extent of competition for HR00112090078 was competed.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV